Read the News and Earn Credit - Click for Credit

For news and views that matter to pediatricians
Click here »

Perspectives in Atopic Dermatitis: Optimizing Outcomes


Bookmark and Share
11/13/12

A CME-certified supplement to Skin & Allergy News.

 

This CME supplement is supported by an educational grant from Valeant Dermatology. Developed from a clinical roundtable, it is jointly sponsored by the University of Louisville Continuing Health Sciences Education and Skin Disease Education Foundation, in affiliation with Global Academy for Medical Education.

  • Faculty
  • Topic Highlights
  • Target Audience
  • Educational Needs
  • Learning Objectives
  • Disclosure
  • Accreditation
  • For CME posttest and Evaluation, please click on here.

Faculty

Lawrence F. Eichenfield, MD (Chair)

Professor of Clinical Pediatrics and Medicine (Dermatology)

Chief, Pediatric and Adolescent Dermatology

University of California, San Diego School of Medicine

Rady Children’s Hospital

San Diego, CA

 

Charles N. Ellis, MD

William B. Taylor Professor of Clinical Dermatology

Associate Chair, Department of Dermatology

University of Michigan Medical Center

Ann Arbor, MI

 

Amy S. Paller, MD

Walter J. Hamlin Professor and Chair of Dermatology

Professor of Pediatics

Northwestern University Feinberg School of Medicine

Attending Physician

Ann & Robert H. Lurie Children’s Hospital of Chicago

Chicago, IL

 

Anthony J. Mancini, MD

Professor of Pediatrics and Dermatology

Northwestern University Feinberg School of Medicine

Head, Division of Pediatric Dermatology

Ann & Robert H. Lurie Children’s Hospital of Chicago

Chicago, IL

 

Eric L. Simpson, MD, MCR

Associate Professor of Dermatology

and Director of Clinical Studies

Oregon Health and Science University

Portland, OR

 

Topic Highlights

  • Perspectives in Atopic Dermatitis-Optimizing
  • Atopic Dermatitis: Epidemiology and Pathogenesis Update
  • Current Issues in Atopic Comorbidities and Preventing the Atopic March
  • Treatment Strategies for Atopic Dermatitis: Optimizing the Available Therapeutic Options
  • Understanding and Managing Atopic Dermatitis in Adult Patients
  • Improving the Patient-Clinician and Parent-Clinician Partnership in Atopic Dermatitis Management

 

Target Audience

This continuing medical education activity has been developed for pediatricians, dermatologists, family practitioners,  and other health care professionals who are involved in the diagnosis and management of patients with atopic dermatitis.

 

Educational Needs

The estimated prevalence of atopic dermatitis (AD) in the United States ranges from 10% to 20%, with a current estimated prevalence of new diagnoses of AD (or eczema) of 11% each year. The disease is most commonly diagnosed in childhood, and most cases resolve before adulthood. Although most cases of AD that persist into adulthood tend to be milder than childhood AD, even mild AD can be a significant burden to adult patients, in terms of quality-of-life and psychosocial issues. Within the past decade, the increased appreciation of the role of the epidermal skin barrier and the discovery of the role of the filaggrin gene in the maintenance of this barrier has led to a new understanding of the pathogenesis of AD. Topical corticosteroids remain the mainstay of therapy for most cases of AD in both children and adults, and topical calcineurin inhbitors have proved to be a valuable addition to the roster of therapeutic options.

 

Experience has shown that strategies such as rotational therapy can optimize the clinical benefits of both of these classes of topical medications. Clinicians need to remain up-to-date on the benefits and risks, as well as the appropriate selection, of all of the available treatments, both topical and systemic. Health practitioners also must be informed about new and emerging developments in the pathogenesis of AD and other atopic diseases. These advances hold promise for future developments in the diagnosis and management of AD.

           

Learning Objectives

After participating in this continuing medical educational activity, clinicians should be able to:

  • Discuss the most recent information on the epidemiology and pathogenesis of AD, and how this is likely to affect the management of patients with AD.
  • Explain how the current and emerging understanding of the role of the epidermal skin barrier should affect—and continue to improve—the day-to-day care of patients with AD.
  • Describe the role of mutations in the filaggrin gene (FLG) in the pathogenesis of AD, and use this understanding to evaluate the results of ongoing clinical studies that address FLG mutations.
  • More effectively individualize patient treatment strategies by considering the full range of current therapeutic options.
  • Reassure patients and/or parents by providing updated information about the risks and benefits of using topical corticosteroid and topical calcineurin inhibitors.
  • Incorporate discussions of quality-of-life and potential psychosocial comorbidities into clinical encounters with adult patients with AD, and be prepared to provide interventions or refer patients for appropriate counseling and therapy.
  • Have improved confidence in using systemic therapy when indicated, and incorporate recommendations for clinical and laboratory monitoring into treatment plans for the duration of such treatment.

 

Disclosure

As a sponsor accredited by the ACCME, CHSE must ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty participating in this CME activity were asked to disclose the following:

  1. Names of proprietary entities producing health care goods or services—with the exemption of nonprofit or government organizations and non–health-related companies—with which they or their spouse/partner have, or have had, a relevant financial relationship within the past 12 months. For this purpose, we consider the relevant financial relationships of a spouse/partner of which they are aware to be their financial relationships.
  2. Describe what they or their spouse/partner received (eg, salary, honorarium).
  3. Describe their role.
  4. No relevant financial relationships.

 

CHSE Committee Members: have no relevant financial relationships with any commercial interests: Joye Dunagan, MA, MSLS; Terri Gipson, MSL; Christopher Jones, MD; Lucy Juett, MS; Lisa J. Pfitzer, MD; Uldis Strepis, PhD; Debbie Thomas; Kathy M. Vincent, MD; Lori Wagner, MD; Stephen Wheeler, MD; CHSE Staff: Jim Creg, Joyce Korfhage, and Kimberly Moore have no relevant financial relationships with any commercial interests.

 

CME REVIEWER: Timothy Brown, MD, Professor, Division of Dermatology, University of Louisville School of Medicine, has no relevant financial relationships with any commercial interests.

 

Lawrence F. Eichenfield, MD, has served as a consultant for Anacor, Bayer, and Onset Therapeutics and as a speaker and consultant for Valeant. He has also been an investigator and consultant for Galderma, and Leo Pharma as well as an investigator for Amgen, Astellas Pharma US, and Stiefel, A GSK Company.

Charles N. Ellis, MD, has served as a consultant for Galderma, Ferndale Laboratories, Medicis, and Novartis.

 

Anthony J. Mancini, MD, has served as a consultant for Quinnova and Valeant as well as a speaker and consultant for Galderma.

 

Amy S. Paller, MD, has received grant research support from Astellas.

 

Eric L. Simpson, MD, MCR, has served as a consultant, investigator, and speaker for Galderma.

 

Joanne Still, BA, Sylvia H. Reitman, MBA, and Shirley V. Jones, MBA, have no relevant financial relationships with any commercial interests.

 

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Louisville School of Medicine Continuing Health Sciences Education (CHSE) and Skin Disease Education Foundation.  CHSE is accredited by the ACCME to provide continuing medical education for physicians.

 

The CHSE designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Term of Approval:  September 2012 – September 30, 2013.

 

Copyright © 2012 by Elsevier Inc.


click me